Bioventus (BVS) Fundamental Analysis: Revenue, Earnings & Valuation

0.14 / 10

Underperform

Fundamentally the stock underperforms, scoring only 0.1/10. Strengths lie in cash‑up and EBIT margin, while profit‑to‑market and net‑income ratios are poor. Overall fundamental rating is Underperform, indicating significant downside risk.

Analysis Checks(5/10)

Revenue-MV

Value0.52

Score1/3

Weight133.42%

1M Return-2.72%

Net cash flow from operating activities / Operating revenue (%)

Value13.14

Score1/3

Weight14.51%

1M Return-0.28%

Profit-MV

Value0.56

Score1/3

Weight151.25%

1M Return-2.85%

Net income-Revenue

Value-0.29

Score1/3

Weight135.39%

1M Return-2.58%

Net profit margin (%)

Value4.80

Score2/3

Weight-36.65%

1M Return0.68%

Cash-UP

Value-0.07

Score3/3

Weight-158.95%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value0.16

Score1/3

Weight198.84%

1M Return-4.08%

EBIT / Total operating revenue (%)

Value9.19

Score2/3

Weight-52.65%

1M Return1.01%

Asset-MV

Value-0.55

Score3/3

Weight-248.51%

1M Return3.88%

Net profit / Total operating revenue (%)

Value4.80

Score2/3

Weight-36.65%

1M Return0.68%

Is BVS fundamentally strong?

BVS scores 0.14/10 on fundamentals and holds a Premium valuation at present. Backed by its 10.98% ROE, 4.80% net margin, 33.47 P/E ratio, 3.33 P/B ratio, and 160.71% earnings growth, these metrics solidify its Underperform investment rating.